Progenics Pharma (PGNX) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
OCCI, MAYS, CRMT, More
Financial Fact:
Net income (loss) per share - diluted: 0.52
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.35 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Accenture downgraded by TD Cowen on AI concerns
- Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
